Low Libido: What Could Be Causing It

How Common Is Low Libido, and Who Does It Affect?

Low sexual desire is one of the most frequently reported concerns in primary care and endocrinology clinics. Population data show it is not rare, not age-restricted, and not limited to one sex. Understanding the baseline prevalence helps clinicians and patients recognize when reduced desire crosses from normal fluctuation into a clinical problem.

The PRESIDE study (N=31,581) found that 36.2% of U.S. women aged 18 to 44 reported hypoactive sexual desire, and 8.9% met full criteria for hypoactive sexual desire disorder (HSDD) when distress was included [1]. In men, the Massachusetts Male Aging Study reported that 17% of men aged 40 to 70 experienced low desire, with rates climbing steeply after age 50 [2]. The European Male Ageing Study (EMAS, N=3,369) confirmed that sexual desire declines in parallel with falling free testosterone levels, though the threshold at which men become symptomatic varies by individual [3].

Age is a factor. It is not the only factor. Young adults on SSRIs, postpartum women, shift workers sleeping fewer than five hours nightly, and athletes on caloric restriction all present with low libido at rates well above age-matched peers [4]. The 2018 Endocrine Society guideline on testosterone therapy noted: "Clinicians should not dismiss sexual symptoms in younger men solely because total testosterone falls within the reference range" [5].

Hormonal Causes: Testosterone, Estrogen, Thyroid, and Prolactin

Low libido has a hormonal explanation in roughly half of cases when structured lab evaluation is performed. The four axes most commonly implicated are the hypothalamic-pituitary-gonadal (HPG) axis, thyroid function, prolactin regulation, and adrenal androgens.

Testosterone. In men, total testosterone below 300 ng/dL on a fasting morning draw is the Endocrine Society's threshold for investigating hypogonadism [5]. The Testosterone Trials (TTrials, N=790) demonstrated that testosterone gel improved sexual desire scores by 0.58 SD over placebo at 12 months in men 65 and older with confirmed low T [6]. In women, testosterone's role is supported by meta-analysis: a Lancet systematic review of 46 RCTs (N=8,480) found that transdermal testosterone significantly increased satisfying sexual events and desire in postmenopausal women [7].

Estradiol. Declining estradiol during perimenopause causes vaginal dryness, dyspareunia, and secondary desire loss. The 2022 North American Menopause Society (NAMS) position statement recommended low-dose vaginal estrogen or systemic hormone therapy for genitourinary syndrome of menopause, which frequently co-occurs with HSDD [8].

Thyroid. Both hypothyroidism and hyperthyroidism impair desire. A cross-sectional study published in the Journal of Clinical Endocrinology & Metabolism (N=3,703) found that women with subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) had 2.3 times the odds of reporting low desire compared with euthyroid controls [9].

Prolactin. Hyperprolactinemia suppresses GnRH pulsatility, reducing downstream testosterone and estradiol. Causes include prolactinomas, antipsychotics (risperidone being the most common offender), and renal failure [10]. A prolactin level above 25 ng/mL in a patient with low desire warrants pituitary MRI.

Medications That Kill Sex Drive

Drug-induced sexual dysfunction is underdiagnosed because clinicians rarely ask about it and patients rarely volunteer the information. Several medication classes have strong evidence linking them to reduced desire.

SSRIs and SNRIs. A meta-analysis in the Journal of Clinical Psychiatry covering 14 RCTs found that sexual dysfunction occurred in 58.4% of patients on SSRIs versus 29.5% on placebo [11]. Paroxetine carries the highest risk. Bupropion, which acts on dopamine and norepinephrine rather than serotonin, shows the lowest rate of sexual side effects among antidepressants and is sometimes added as an adjunct specifically to counteract SSRI-related desire loss.

Opioids. Chronic opioid therapy suppresses the HPG axis. "Opioid-induced androgen deficiency (OPIAD) is present in up to 90% of men on long-term opioid therapy and is a reversible cause of hypogonadism," according to a 2014 review in the Journal of Clinical Endocrinology & Metabolism [12]. Testosterone levels often recover within weeks of opioid taper.

5-alpha reductase inhibitors. Finasteride 1 mg (Propecia) and dutasteride reduce dihydrotestosterone. The Prostate Cancer Prevention Trial (N=18,882) recorded decreased libido in 6.4% of finasteride users versus 5.1% on placebo, though post-marketing reports suggest higher real-world rates [13].

Hormonal contraceptives. Combined oral contraceptives raise sex hormone-binding globulin (SHBG), which binds free testosterone. Some women report desire loss that persists even after discontinuation if SHBG levels remain elevated [14].

Other common offenders include spironolactone, GnRH agonists (leuprolide), antiandrogens, beta-blockers (especially propranolol), and gabapentinoids.

Chronic Disease and Metabolic Disruption

Systemic illness affects sexual desire through overlapping pathways: direct hormonal suppression, fatigue, pain, neurotransmitter changes, and medication burden.

Type 2 diabetes. The NHANES analysis found that men with diabetes had 1.55 times the odds of reporting low desire compared to non-diabetic men after adjustment for age, BMI, and depression [15]. Insulin resistance itself lowers SHBG and alters the testosterone-to-estradiol ratio through increased aromatase activity in visceral fat.

Obesity. Each one-unit increase in BMI above 25 is associated with a 2% decline in total testosterone in men [3]. Weight loss reverses this. The STEP-1 trial (N=1,961) showed 14.9% mean body weight reduction with semaglutide 2.4 mg at 68 weeks [16], and observational follow-up data suggest that GLP-1-mediated weight loss may improve sexual function scores, though dedicated RCTs are ongoing.

Chronic kidney disease. Uremia disrupts the HPG axis at every level. Prolactin rises. Testosterone falls. Zinc deficiency compounds the problem.

Obstructive sleep apnea. A study in JAMA (N=531) demonstrated that one week of sleep restriction to five hours per night lowered daytime testosterone by 10 to 15% in young healthy men [17]. Treatment of OSA with CPAP partially restores testosterone levels and desire.

Chronic pain and fatigue syndromes. Conditions like fibromyalgia, chronic fatigue syndrome, and rheumatoid arthritis reduce desire through pain itself, opioid use, and central sensitization.

Psychological and Relational Factors

Not every case of low libido has a lab abnormality behind it. Psychological contributors are common, frequently co-occur with hormonal issues, and respond to targeted intervention.

Depression. The relationship is bidirectional. Depression reduces desire through serotonergic and dopaminergic changes in the nucleus accumbens and prefrontal cortex. Low desire then reinforces depressive cognitions about inadequacy. The challenge is distinguishing depression-driven low libido from SSRI-driven low libido in treated patients.

Anxiety. Performance anxiety is well-documented in men, but generalized anxiety also suppresses desire in women. Sympathetic nervous system activation diverts blood flow and attention away from arousal circuits.

Relationship distress. A 2019 study in the Archives of Sexual Behavior (N=2,996 couples) found that relationship satisfaction was the single strongest predictor of sexual desire in both men and women, exceeding even hormonal variables [18]. Gottman's research on the "Four Horsemen" (criticism, contempt, defensiveness, stonewalling) maps directly onto desire loss in long-term partnerships.

Body image. Negative body image predicts desire loss independent of actual BMI, particularly in women. This can complicate GLP-1 treatment, where rapid weight loss sometimes produces loose skin that worsens body image before it improves overall confidence.

Trauma history. Past sexual trauma is a significant but often unscreened contributor. The DSM-5 explicitly notes that HSDD diagnosis requires assessment of trauma history before attributing symptoms to a primary desire disorder [19].

How Low Libido Is Diagnosed

Diagnosis follows a structured approach: detailed history, validated questionnaires, targeted labs, and selective imaging.

History. The clinician should distinguish lifelong versus acquired low desire, generalized versus situational (present with all partners versus only one), and should catalogue all medications, supplements, recreational substances, sleep patterns, and relationship context. A single direct question often unlocks the diagnosis.

Questionnaires. The Decreased Sexual Desire Screener (DSDS) is a five-item validated tool for identifying HSDD in women. The International Index of Erectile Function (IIEF) includes a desire domain for men. These instruments standardize what is otherwise a subjective complaint.

Lab panel. The Endocrine Society recommends the following minimum workup when low desire is associated with other hypogonadal symptoms [5]:

• Total testosterone (fasting, drawn before 10 AM)
• Free testosterone (calculated or equilibrium dialysis)
• SHBG
• LH and FSH (to differentiate primary from secondary hypogonadism)
• Prolactin
• TSH
• Estradiol (in men to assess aromatization; in women to assess menopausal status)
• CBC and metabolic panel

Imaging. Pituitary MRI is indicated when prolactin exceeds 50 ng/mL, when LH/FSH are inappropriately low with low testosterone, or when visual field defects are present.

Evidence-Based Treatment Options

Treatment depends on the identified cause. Effective therapy exists for hormonal, pharmacological, and psychological drivers of low desire.

Testosterone replacement in men. The TTrials showed meaningful improvement in desire at 12 months [6]. Options include topical gels (testosterone 1.62%, applied daily), intramuscular injections (testosterone cypionate 100 to 200 mg every 1 to 2 weeks), and subcutaneous pellets. Monitoring includes hematocrit, PSA, and lipids at 3, 6, and 12 months.

Testosterone in women. The 2019 Global Consensus Position Statement on testosterone therapy for women endorsed transdermal testosterone at doses approximating 5 mg daily for postmenopausal women with HSDD, citing consistent benefit across RCTs [7]. No FDA-approved female testosterone product exists in the U.S., so compounded formulations are commonly used.

Flibanserin (Addyi). Approved for premenopausal HSDD. Pooled analysis of three phase III trials (BEGONIA, DAISY, VIOLET; combined N=2,400) showed 0.5 additional satisfying sexual events per month versus placebo and a clinically meaningful improvement on the Female Sexual Distress Scale [20]. The drug requires daily dosing and carries a boxed warning against alcohol use.

Bremelanotide (Vyleesi). A melanocortin receptor agonist given as a subcutaneous injection 45 minutes before anticipated sexual activity. The RECONNECT trials (N=1,247) demonstrated significant improvement in desire scores versus placebo [21]. Nausea occurs in about 40% of patients with the first dose but diminishes with subsequent use.

Medication switching. For SSRI-induced low libido, switching to bupropion or adding bupropion 150 mg XL is the most evidence-supported approach. Mirtazapine and vilazodone also have lower sexual side effect profiles.

Psychotherapy. Cognitive behavioral therapy (CBT) and mindfulness-based sex therapy have RCT support for HSDD in women. Sensate focus exercises, originally developed by Masters and Johnson, remain a cornerstone of couples-based sex therapy.

Lifestyle modification. Resistance training three or more days per week raises free testosterone in men. Sleep optimization to 7 to 9 hours improves HPG axis signaling. Moderate alcohol reduction (below 14 drinks per week for men, below 7 for women) removes a suppressant effect on central arousal.

When to See a Doctor and What to Expect

Low desire lasting longer than three months and causing personal distress meets the DSM-5 duration criterion for HSDD [19]. That three-month mark is a reasonable trigger for clinical evaluation.

At a first visit, expect the clinician to spend 15 to 20 minutes on sexual and medical history, order the lab panel described above, and schedule a follow-up in 2 to 4 weeks to review results. If a hormonal cause is confirmed, treatment can begin at that second visit. If labs are normal, referral to a sex therapist or psychiatrist is appropriate.

Red flags that warrant urgent evaluation: sudden onset of desire loss with headaches or visual changes (possible pituitary mass), galactorrhea (prolactinoma), new-onset fatigue with weight gain and cold intolerance (hypothyroidism), or desire loss accompanied by suicidal ideation (depression requiring immediate psychiatric care).

The prognosis for low libido is generally good when the cause is identified. Hormonal causes respond to replacement. Drug-induced causes resolve with medication changes. Psychological causes respond to therapy. The patients who struggle most are those who never raise the topic with their clinician in the first place.